Applied Immune Technologies

Company Overview

Snapshot

Founded in February 2006 by Aya Yakobovitz, Applied Immune Technologies operated with 1–10 employees. The company secured funding across two rounds from Pontifax, totaling $4.4 million. A significant milestone occurred in January 2016 when the company was acquired by Adicet Bio.

Business overview

Applied Immune Technologies (AIT) is a drug development company focused on T-cell-receptor-like (TCRL) antibodies for therapeutic and diagnostic applications. The company's core technology platforms identify and validate novel MHC-based targets and develop human recombinant TCRL antibodies designed to bind to intracellular peptide/MHC complexes with the specificity of cytotoxic T-cell killer cells. AIT's technologies aim to create a pipeline of therapeutic TCRL antibodies for intracellularly derived, disease-specific targets typically inaccessible to conventional antibodies, also offering diagnostic applications in vaccine design, validation, and monitoring, as well as antigen presentation analysis in various diseases. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.

Strategic signal

Applied Immune Technologies was acquired by Adicet Bio in January 2016, marking a strategic exit for the company. This acquisition indicates the value and potential seen in AIT's T-cell-receptor-like (TCRL) antibody technology for therapeutic and diagnostic applications, particularly in cancer, viral, and autoimmune diseases. For investors, this event signals successful validation of AIT's innovative approach to drug development and its integration into a larger biopharmaceutical entity focused on advancing cell therapies.

Company Intelligence Q&A

When was Applied Immune Technologies founded?

Applied Immune Technologies was founded in February 2006.

Who founded Applied Immune Technologies?

Applied Immune Technologies was founded by Aya Yakobovitz.

What is the primary focus of Applied Immune Technologies?

Applied Immune Technologies specializes in developing T-cell-receptor-like (TCRL) antibodies for therapeutic and diagnostic applications in cancer, viral, and autoimmune diseases.

When was Applied Immune Technologies acquired?

Applied Immune Technologies was acquired by Adicet Bio in January 2016.

Which investor participated in a funding round for Applied Immune Technologies?

In April 2010, Pontifax participated in a funding round for Applied Immune Technologies.